Atrial fibrillation (AF) is an important cause of preventable, disabling stroke and is increasingly prevalent with advancing age. As life expectancies increase around the world, AFrelated stroke is a growing global public health concern. Most AF patients are elderly (C75 years old) and increasing age is a consistent independent risk factor for AF-associated stroke. Warfarin anticoagulation is highly effective for stroke prevention in AF patients, but is underutilized especially in the elderly.
INTRODUCTION
Atrial fibrillation (AF) is a major risk factor for disabling ischemic stroke due to embolism from the left atrial appendage. The prevalence of AF increases with increasing age (Fig. 1 ) [1] . The true prevalence of AF is difficult to assess, as a significant proportion of patients will be asymptomatic or have subclinical disease; however, it is estimated that at least 10% of elderly people (C75 years old) have AF [2] and 56% of people with the condition are elderly [3, 4] . The influence of AF on health increases with age, and 71% of strokes that occur in patients with AF are in those aged over 70 years [5] . The outcome of patients following stroke due to AF is worse, on average, compared with non-AFrelated strokes [6] .
Antiplatelet agents and oral anticoagulants are effective in reducing the risk of stroke in AF patients, with oral anticoagulants being more effective in reducing the risk of ischemic strokes than antiplatelet agents [7] . However, increasing age is associated with underutilization of warfarin [8] . Clinical data on elderly patients are limited as they are often underrepresented in randomized controlled trials (RCTs). Furthermore, older patients have an increased risk of hemorrhage and often have multiple comorbidities including chronic kidney disease (CKD), anemia, hypertension, diabetes and an increased risk of falls.
In recent years, novel selective oral anticoagulants have become available. All undergo substantial renal excretion [9] , but are at least as effective as adjusted-dose warfarin in reducing the risk of stroke. They are also associated with a decreased risk of intracranial hemorrhage in patients with AF [10] [11] [12] . While it is likely that the new generation of novel oral anticoagulants will eventually replace warfarin, the role of these agents in the elderly remains to be fully defined. This review examines the use of novel oral anticoagulants in patients aged C75 years with AF, focusing on information from randomized trials. In addition, the relationship between age, AF and stroke risk, as well as the current evidence for oral anticoagulants and antiplatelet agents for stroke prevention in the elderly, will be considered.
Fig. 1
Prevalence of AF with increasing age [1] . Error bars indicate 95% confidence intervals. Numbers indicate number of men and women with atrial fibrillation in each category. Adapted from Go et al. [1] 
METHODS
This review article incorporates data from observational studies, review articles, available guidelines and RCTs on the use of anticoagulants and antiplatelet agents for stroke prevention in elderly patients. Relevant literature was obtained with a MEDLINE search. The literature was chosen based on their inclusion and influence on current practice.
DISCUSSION

Age and AF
AF is the most common clinically significant arrhythmia and is associated with significant mortality and morbidity [13] . The number of patients with AF is forecast to increase as will the proportion of elderly patients [1] . Adjusting for age, risk factors for AF include valvular heart disease, congestive heart failure, diabetes and hypertension, all of which are more common in the elderly.
AF independently increases stroke risk by fivefold in the general population and accounts for a greater proportion of strokes with increasing age [5] . The risk of thromboembolism in AF increases sharply with age over 65 years, with the relative risk increasing approximately 1.45-fold per decade [7] . Age is a strong and consistent predictor of stroke in patients with AF and is included in all stroke risk stratification schemes for AF [14, 15] .
While increasing age as a risk factor for AF and stroke is continuous, age C75 years is arbitrarily used to dichotomize risk in cohort analyses and systematic reviews [16] .
Other independent risk factors for stroke include previous transient ischemic attacks or stroke, heart failure, hypertension and diabetes.
The Congestive cardiac failure, Hypertension, Age C75, Diabetes and previous Stroke or transient ischemic attack (CHADS 2 ) score is a simple, commonly used stroke risk stratification scheme for patients with AF [17] . It was developed by incorporating the Stroke Prevention in AF (SPAF) and AF Investigators (AFI) risk schemes and was validated in a cohort of patients with AF admitted to hospital [18] [19] [20] ( Table 1) . Most guidelines now recommend the use of vitamin K antagonists in patients with a CHADS 2 score of 1 or greater. However, the recommendations have to be balanced against the risk of hemorrhage, which is higher during anticoagulation in the elderly. [21, 22] . In addition to the risk factors identified in the CHADS 2 score, CHA 2 DS 2 -VASc incorporates one point each for sex, history of vascular disease and age C65 years. Age C75 years will incur an extra point.
Female sex is incorporated into CHA 2 DS 2 -VASc as an independent predictor of stroke in AF despite the absence of a clear biologically plausible explanation for the underlying etiology. Large differences in stroke risk between the sexes were noted in the AFI metaanalysis in 1990 [23] and were consistent with large observational studies [24] [25] [26] . The difference in stroke risk between the sexes was greatest with increasing age. Elderly women had a significantly higher risk of stroke compared with similarly aged men [24] .
The additional components within CHA 2 DS 2 -VASc compared with CHADS 2 was shown to improve discrimination in patients with a CHADS 2 score of 1 by identifying patients aged \75 years with sufficiently low absolute stroke risk who may not be expected to benefit from anticoagulant therapy [15, 22] ( Fig. 2) . Conversely, all patients aged C75 years would be considered for anticoagulation, as the additional point for older age would give a CHA 2 DS 2 -VASc score of at least 2 [27, 28] .
Renal function declines gradually with age and CKD is common in patients with AF. Onethird of all outpatients with AF and over 50% of elderly patients with AF have CKD (estimated glomerular filtration rate (eGFR) \60 ml/min) [29, 30] . CKD is an independent predictor of stroke risk in patients with AF (HR 1.5) [29, 31, 32] and the impact of Stage 3 CKD on stroke risk is similar to other predictors used in the CHADS 2 score [14] . However, the precise mechanisms underlying increased stroke risk in CKD are unclear and have not been incorporated into any of the commonly used risk stratification scores. There are less data stratifying stroke risk in Stage 4 CKD and end stage renal failure, but AF remains an independent risk factor for ischemic stroke [33] . Fig. 2 Comparative rate of death, stroke and systemic embolism between CHADS 2 versus CHA 2 DS 2 -VASc [15, 22] Warfarin in Elderly Patients with AF Most ischemic strokes in patients with AF are due to cardiogenic embolism from thrombi originating from the left atrial appendage; however, up to 25% of cases may be caused by intrinsic small vessel cerebrovascular disease with co-existing vascular risk factors such as coronary artery disease, hypertension and diabetes [34] . Aspirin appears to exert most of its effect via prevention of non-cardiogenic embolic events, while warfarin is far superior to aspirin in preventing cardio-embolic ischemic strokes [34] . At most, aspirin reduces the relative risk of stroke by about 25% in patients with AF. Most of the reduction in stroke risk with aspirin leads to a reduction in transient ischemic attacks and non-disabling strokes [35] . Dose-adjusted warfarin reduces the relative risk of stroke by about 60% in patients with AF compared with placebo [3, 28, 36] . With increasing age, the benefit of aspirin in preventing stroke decreases and appears to be ineffectual when patients enter their eighth decade, whereas the risk reduction derived from warfarin anticoagulation is preserved with age [7] .
The most serious side effect of warfarin is bleeding, including intracranial bleeding. Age is an independent risk factor for bleeding on anticoagulant therapy [37, 38] and warfarin is associated with an increased risk of bleeding compared with aspirin therapy (HR 1.71) [39] .
The absolute risk reduction of all strokes and cardiovascular events is not substantially offset by the proportionally smaller increased risk of hemorrhage in the general population. Elderly patients are likely to derive the greatest benefit from warfarin therapy, but have the highest risk of hemorrhage. Elderly patients are underrepresented in most RCTs assessing the use of warfarin in AF, with patients aged C75 years representing only 20% of patients in most RCTs involving oral anticoagulants in AF [40] . The exception is the Birmingham AF Trial in the Aged (BAFTA), which was restricted to AF patients C75 years old with no contraindications to hemorrhage. BAFTA participants were randomized to warfarin versus aspirin, and there was no increased risk of major hemorrhage with anticoagulation. The rates of hemorrhage in BAFTA were lower when compared with a previous subgroup metaanalysis of anticoagulation in patients aged C75 years. 40% of patients in BAFTA had already been established on warfarin and probably underestimated bleeding risk compared with warfarin-naïve patients [41] .
Prediction of Hemorrhage in Elderly
Patients on Warfarin [19, 20] . The score is relatively easy to use and provided modest predictive value for major hemorrhage in patients on oral anticoagulants (C-statistic 0.69) in the Euro Heart Survey cohort [42] . However, HAS-BLED requires validation in other patient populations such as the elderly before it is adopted universally. Other bleeding risk prediction scores for warfarin anticoagulation have been proposed, but none have been adequately validated in our view [38, 43] . Many of the factors that predict hemorrhage in these risk prediction scores are also risk factors for stroke. Therefore, the use of risk stratification scores in elderly patients with AF is likely to be limited as a result (Table 1) . Based on CHA2DS2-VASc risk factors, men with no hypertension, diabetes or prior stroke but who had AF in the SPAF trials were at the lowest risk of stroke while on aspirin therapy, with a stroke rate of 1.6%/year (95% CI 0.7-3.9) [7] . Men aged C75 years participating in BAFTA and without other CHA 2 DS 2 -VASc risk factors had a stroke rate of 2.1%/year (95% CI 0.77-4.6) during aspirin therapy [27] . The margin of error for these rates is wide and includes rates that would warrant anticoagulation. Elderly women with AF carry a higher risk of stroke than elderly men [28] . It is unclear whether patients aged C75 years with AF who are at low risk can be reliably identified.
Randomized Trials Comparing Warfarin Versus Aspirin in Patients with AF Aged ‡75 years
A meta-analysis of randomized trials, including 29 trials involving 28,044 patients with a mean age of 71 years, confirmed the superiority of warfarin over anti-platelet agents in reducing stroke risk. The absolute increase in major extracranial hemorrhage on warfarin compared with aspirin was overshadowed by the absolute reduction in stroke risk in patients with AF [44] .
However, only 2,680 (10%) participants in these randomized trials were C75 years old despite the fact that most patients with AF were within this age group. However, based on the AFI pooled meta-analysis from six trials [39] and the results of BAFTA [45] , it is clear that warfarin anticoagulation reduces the risk of stroke to a greater extent than aspirin in elderly patients with AF (Table 2 ) [46, 47] . In BAFTA, elderly patients on oral anticoagulants had a 52% relative risk reduction in all strokes or systemic embolism compared with aspirin and had no significant increase in intracranial or extracranial hemorrhage [45] . The risk of major hemorrhage was lower than that noted in the AFI pooled meta-analysis [39] . This may be explained by the use of a contemporary International Normalized Ratio (INR) target range of 2-3. In addition, 40% of patients in BAFTA were not warfarin naïve and were already established on warfarin prior to enrollment compared with the warfarin-naïve C75 years for the prevention of ischemic stroke [3, 28] . Despite this, the uptake of oral anticoagulants among patients C75 years remains low. In our view, all patients with AF C75 years old (and especially women) should be considered for anticoagulation prophylaxis to prevent stroke in the absence of any clear contraindications, provided it can be initiated and monitored safely [7] . From the data summarized above, the risk of stroke for these patients is sufficiently high and the efficacy of warfarin is established.
Challenges with Warfarin Anticoagulation in Elderly Patients with AF
While all patients aged C75 years should be considered for warfarin anticoagulation, the decision to prescribe warfarin for an individual patient should take into consideration risk of stroke versus hemorrhage, practicalities for monitoring anticoagulation and patient preference [49, 50] . Furthermore, patients with AF aged C75 years are more likely to experience significant co-morbidities on multiple medications. [45] .
Risk of Falls
Other risk factors for intracranial hemorrhage in the elderly are an increased risk of falls and associated neuropsychiatric disease [38, 56] .
Risk of falls and intra-cerebral hemorrhage with warfarin are often quoted as a reason to avoid anticoagulation. However, if a patient has a 5% annual risk of stroke from AF, it has been estimated that the patient would need to fall over 295 times to offset the benefit of oral 
Chronic Kidney Disease and Anemia
The prevalence of renal disease increases with advancing age [30] . Patients with CKD have three times the risk of AF compared with patients without CKD and are likely to be on warfarin anticoagulation. However, stage 3 CKD is associated with twice the rate of major bleeding during warfarin anticoagulation [12, 58] . These higher rates of major bleeding were not adjusted for age. In a longitudinal cohort analysis, stage 3 CKD was not an independent predictor of hemorrhage during warfarin anticoagulation [59] . While the Anticoagulation and Risk Factors In AF (ATRIA) dataset showed CKD with an estimated creatinine clearance (eCrCl) of \30 ml/min was an independent predictor of major hemorrhage (HR 4.3, p\0.001), it has not been sufficiently validated for general clinical use [43] . Whist patients with CKD are at increased risk of anemia, the same ATRIA dataset concluded anemia (hemoglobin \13 g/dl in men; \12 g/dl in women) was an independent predictor of hemorrhage (HR 4.2, p\0.001) [43] . Anemia is prevalent in the elderly and is estimated to affect 23.9% of patients over the age of 70 years [60, 61] .
Patient Preferences for Anticoagulation
The decision to take anticoagulation for AF requires consideration of the potential risks and benefits. Physicians and patients can differ in how they weigh up these factors when arriving at a decision to take oral anticoagulants.
Patients at risk of developing AF, who have no previous history of stroke, place more value on the avoidance of stroke and less value on the avoidance of bleeding than physicians [62] . participants C75 years old and provide substantial evidence for their efficacy in this age group [10] [11] [12] 47] (Table 3) .
Dabigatran, apixaban and rivaroxaban do not require regular anticoagulation monitoring or frequent dose adjustments; however, a specific antidote to rapidly reverse the anticoagulant effect of these agents in the event of an acute hemorrhage is not available (other than acute hemodialysis for agents such as dabigatran) [63] (Table 4) . These novel anticoagulant agents have been approved for clinical use and have been shown to be at least non-inferior to dose-adjusted warfarin for stroke prevention. 
Dabigatran
In the Randomized Evaluation of Long-term Anticoagulant TherapY (RE-LY) randomized trial, two doses of dabigatran (110 mg and 150 mg twice daily) were compared with warfarin [10] . Both doses of dabigatran in RE-LY were associated with a lower risk of major hemorrhage in patients \75 years, but this was not the case in those aged C75 years. The risk of major hemorrhage and extracranial hemorrhage rose more steeply with dabigatran than warfarin with increasing age. Dabigatran 150 mg twice daily was associated with an increased risk of major extracranial bleeding in elderly patients compared with warfarin.
However, the risk of intracranial bleeding remained lower with both doses of dabigatran with no evidence of interaction with age [64] .
Dabigatran 150 mg bid was associated with a lower risk of strokes or systemic embolism compared to warfarin and there was no association between dabigatran and the risk of myocardial infarctions [10] . As dabigatran is dependent on renal excretion, it is contraindicated in severe renal disease (eCrCl \30 ml/min). In the USA, only dabigatran 150 mg bid is licensed for use in the prevention of strokes in patients with AF, while in Canada and the UK dabigatran 110 mg bid is also licensed for use in patients at increased risk of bleeding (older patients [80 years, eCrCl 30-60 ml/min or low body weight).
Rivaroxaban
In contrast to the other novel anticoagulants currently on the market, rivaroxaban is dosed daily ( [47] .
The dose of apixaban was reduced from 5 mg bid to 2.5 mg bid in participants who had a serum creatinine concentration B1.5 mg/dl (133 lmol/l) and either age C80 years or a body weight B60 kg in both studies. When compared against warfarin, apixaban was more effective in reducing strokes and all-cause mortality and had a lower risk of major bleeding with no significant age interaction [12] . Those participants with at least moderate renal impairment (eCrCl 25-50 ml/min) had half the rate of major hemorrhage with apixaban (3.3%) versus warfarin (6.7%) [66] .
When compared with aspirin in patients deemed unsuitable for warfarin in the AVERROES study, apixaban was superior to aspirin in preventing stroke or systemic embolism in patients with AF, including those aged C75 years [47] . There was no significant increase in risk of major bleeding in patients C75 years. In addition, there was no significant difference in the risk of major bleeding in patients with stage 3 CKD. The results of the AVERROES study have significant implications for at least 30% of patients who are considered ideal candidates for anticoagulation therapy and are at risk of stroke, but are not on warfarin [67] . This is particularly relevant in the elderly as over 50% of patients C75 years who are at risk of strokes due to AF are not on anticoagulation therapy [26, 48] .
Comparisons Between Novel Oral Anticoagulants
The use of novel anticoagulants to reduce stroke risk in patients remains an exciting avenue for further study. 
